These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25218152)

  • 1. Is the prescribing behavior of Chinese physicians driven by financial incentives?
    Chen C; Dong W; Shen JJ; Cochran C; Wang Y; Hao M
    Soc Sci Med; 2014 Nov; 120():40-8. PubMed ID: 25218152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care.
    Wettermark B; Pehrsson A; Juhasz-Haverinen M; Veg A; Edlert M; Törnwall-Bergendahl G; Almkvist H; Godman B; Granath F; Bergman U
    Qual Prim Care; 2009; 17(3):179-89. PubMed ID: 19622268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health financing policies. Providers' opinions and prescribing behavior in rural China.
    Dong H; Bogg L; Rehnberg C; Diwan V
    Int J Technol Assess Health Care; 1999; 15(4):686-98. PubMed ID: 10645110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in prescribing behaviors after implementing drug reimbursement rate reduction policy in Taiwan: implications for the medicare system.
    Chu HL; Liu SZ; Romeis JC
    J Health Care Finance; 2008; 34(3):45-54. PubMed ID: 18468378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids.
    Li Y; Xu J; Wang F; Wang B; Liu L; Hou W; Fan H; Tong Y; Zhang J; Lu Z
    Health Aff (Millwood); 2012 May; 31(5):1075-82. PubMed ID: 22566449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs: evidence from Taiwan.
    Liu YM; Yang YH; Hsieh CR
    J Health Econ; 2009 Mar; 28(2):341-9. PubMed ID: 19091433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse pharmaceutical payment incentives and providers' behaviour: the emergence of GP-owned gateway pharmacies in Taiwan.
    Lee YC; Huang KH; Huang YT
    Health Policy Plan; 2007 Nov; 22(6):427-35. PubMed ID: 17901065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive drug prescribing in Grampian.
    Ross S; Macleod MJ
    Br J Clin Pharmacol; 2005 Sep; 60(3):300-5. PubMed ID: 16120069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New medicines in primary care: a review of influences on general practitioner prescribing.
    Mason A
    J Clin Pharm Ther; 2008 Feb; 33(1):1-10. PubMed ID: 18211610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing the prescription of drugs of different price levels.
    Semark B; Engström S; Brudin L; Tågerud S; Fredlund K; Borgquist L; Petersson G
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):286-93. PubMed ID: 23349104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of reimbursement on medical decision making: do physicians alter treatment in response to a managed care incentive?
    Melichar L
    J Health Econ; 2009 Jul; 28(4):902-7. PubMed ID: 19395103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a behaviour independent financial incentive on prescribing behaviour of general practitioners.
    Martens JD; Werkhoven MJ; Severens JL; Winkens RA
    J Eval Clin Pract; 2007 Jun; 13(3):369-73. PubMed ID: 17518801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriate medication prescribing in elderly patients: how knowledgeable are primary care physicians? A survey study in Parma, Italy.
    Maio V; Jutkowitz E; Herrera K; Abouzaid S; Negri G; Del Canale S
    J Clin Pharm Ther; 2011 Aug; 36(4):468-80. PubMed ID: 21729112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How does the pharmaceutical industry influence prescription? A qualitative study of provider payment incentives and drug remunerations in hospitals in Shanghai.
    Yang W
    Health Econ Policy Law; 2016 Oct; 11(4):379-95. PubMed ID: 26918751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global budgets and provider incentives: hospitals' drug expenditures in Taiwan.
    Chou SY; Deily ME; Lien HM; Zhang JH
    Adv Health Econ Health Serv Res; 2010; 22():103-22. PubMed ID: 20575230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.
    Pichetti S; Sermet C; Godman B; Campbell SM; Gustafsson LL
    Appl Health Econ Health Policy; 2013 Jun; 11(3):205-18. PubMed ID: 23609765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring the effects of managed care on physicians' perceptions of their personal financial incentives.
    Mitchell JM; Hadley J; Sulmasy DP; Bloche JG
    Inquiry; 2000; 37(2):134-45. PubMed ID: 10985108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of generic versus brand-name antidepressants in a regulated prescription drug market: evidence from Taiwan.
    Liu YM; Ou HT; Yang YK
    J Ment Health Policy Econ; 2014 Dec; 17(4):163-72. PubMed ID: 25599280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospital payment schemes and high-priced drugs: Evidence from the French Add-on List.
    Rachet-Jacquet L; Toulemon L; Rochaix L
    Health Policy; 2021 Jul; 125(7):923-929. PubMed ID: 34001403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.